|
QNCX Quince Therapeutics Inc 1662774 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$35,912,000.00 |
| Balance Sheet |
|
Current Assets
|
$25,580,000.00 |
|
Assets
|
$26,623,000.00 |
|
Current Liabilities
|
$8,768,000.00 |
|
Liabilities
|
$10,951,000.00 |
|
Equity
|
$15,672,000.00 |
|
Shares Out
|
13790794.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-7,627,000.00 |
|
Investing Cash Flow
|
$12,000,000.00 |
| Market Analysis |
Market Cap
|
$317,601,985.82 |
|
Price
|
$24.21 |
|
BVPS
|
1.14 |
|
PB
|
20.20 |
|
EPS
|
3.60 |
|
FCF
|
$-7,627,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:43 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:43 |
|
| Apr |
May |
Jun |
|
|
2026-04-10 |
-1.68 |
2026-05-11 |
2.88 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-11 |
-0.34 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-12 |
-0.25 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view QNCX documents filed with the SEC.
QNCX Filings
Clear
